Tempest Inks $50M Stock Purchase Deal With Lincoln Park
TPST sits 43% above its 52-week low of $0.84.
Summary
Tempest Therapeutics entered a $50 million common stock purchase agreement with Lincoln Park, according to an SEC filing. The deal provides a flexible equity line, allowing Tempest to sell shares to Lincoln Park over time at prevailing market prices. This follows a series of capital-raising efforts, including warrant exercises and an S-3 registration, as the company works to address its going concern warning and Nasdaq listing deficiencies. The agreement offers a potential funding source but does not guarantee immediate cash; actual proceeds depend on future share sales. Investors will watch how quickly Tempest draws on this facility and whether it dilutes existing shareholders.
At the time of this announcement, TPST was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7M. The 52-week trading range was $0.84 to $12.23. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.